A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia

Janice P. Dutcher, Deborah Coletti, Elisabeth Paietta, Peter H. Wiernik

Research output: Contribution to journalArticle

30 Scopus citations

Abstract

Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.

Original languageEnglish (US)
Pages (from-to)375-380
Number of pages6
JournalLeukemia Research
Volume21
Issue number5
DOIs
StatePublished - May 1997

Keywords

  • Accelerated phase CML
  • Chronic myeloid leukemia (CML)
  • Interferon
  • Leukemia
  • Plicamycin
  • Therapy-CML

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia'. Together they form a unique fingerprint.

  • Cite this